Joselin M. Vargas

Joselin M. Vargas

Auto-generated profile, based on publicly available information

Joselin M. Vargas

Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
OOOlusegun O. Onabajo
Olusegun O. Onabajo
ABA. Rouf Banday
A. Rouf Banday
MSMegan Stanifer
Megan Stanifer
WYWusheng Yan
Wusheng Yan
AOAdeola Obajemu
Adeola Obajemu
LPLudmila Prokunina-Olsson
Ludmila Prokunina-Olsson

1 December 2017 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
AOAdeola A Obajemu
Adeola A Obajemu
NRNina Rao
Nina Rao
KDKari A Dilley
Kari A Dilley
JVJoselin M. Vargas
Joselin M. Vargas
FSFaruk Sheikh
Faruk Sheikh
OOOlusegun O Onabajo
Olusegun O Onabajo
Type III IFNs are important mediators of antiviral immunity. IFN-λ4 is a unique type III IFN because it is produced only in individuals who carry a dG allele of a genetic variant rs368234815-dG/TT. Counterintuitively, those individuals who can produce IFN-λ4, an antiviral cytokine, are also less likely to clear hepatitis C virus infection. In this study, we searched for unique functional properties of IFN-λ4 that might explain its negative effect on hepatitis C virus clearance. We used fresh primary human hepatocytes (PHHs) treated with recombinant type III IFNs or infected with Sendai virus to model acute viral infection and subsequently validated our findings in HepG2 cell line models. Endogenous IFN-λ4 protein was detectable only in Sendai virus–infected PHHs from individuals with the dG allele, where it was poorly secreted but highly functional, even at concentrations < 50 pg/ml. IFN-λ4 acted faster than other type III IFNs in inducing antiviral genes, as well as negative regulators of the IFN response, such as USP18 and SOCS1. Transient treatment of PHHs with IFN-λ4, but not IFN-λ3, caused a strong and sustained induction of SOCS1 and refractoriness to further stimulation with IFN-λ3. Our results suggest unique functional properties of IFN-λ4 that can be important in viral clearance and other clinical conditions.

22 March 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
ABA. Rouf Banday
A. Rouf Banday
OOOlusegun O. Onabajo
Olusegun O. Onabajo
SLSeraph Han-Yin Lin
Seraph Han-Yin Lin
AOAdeola Obajemu
Adeola Obajemu
JVJoselin M. Vargas
Joselin M. Vargas
LPLudmila Prokunina-Olsson
Ludmila Prokunina-Olsson
APOBEC3A (A3A) and APOBEC3B (A3B) enzymes drive APOBEC-mediated mutagenesis. Identification of factors affecting the activity of these enzymes could help modulate mutagenesis and associated clinical outcomes. Here, we show that canonical and alternatively splicedA3AandA3Bisoforms produce corresponding mutagenic and non-mutagenic enzymes. Increased expression of the mutagenicA3Bisoform predicted shorter progression-free survival in bladder cancer. We demonstrate that the production of mutagenic vs. non-mutagenic A3B protein isoforms was considerably affected by inclusion/skipping of exon 5 inA3B. Furthermore, exon 5 skipping, resulting in lower levels of mutagenic A3B enzyme, could be increased in vitro. Specifically, we showed the effects of treatment with an SF3B1 inhibitor affecting spliceosome interaction with a branch point site in intron 4, or with splice-switching oligonucleotides targeting exon 5 ofA3B. Our results underscore the clinical role of A3B and implicate alternative splicing ofA3Bas a mechanism that could be targeted to restrict APOBEC-mediated mutagenesis.

23 April 2018 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
NMNaveen A. Mallangada
Naveen A. Mallangada
JVJoselin M. Vargas
Joselin M. Vargas
STSwaroopa Thomas
Swaroopa Thomas
MDMatthew G. DiGiovanni
Matthew G. DiGiovanni
BVBrandon M. Vaeth
Brandon M. Vaeth
GMGerardo Mackenzie
Gerardo Mackenzie